These emerging treatments, Semaglutide , represent a groundbreaking advancement in addressing type 2 diabetes and potentially other conditions . They are classified as GLP-1 pathway agonists , meaning these substances to mimic the body's GLP-1 hormone , boosting metabolic production and click here suppressing appetite . Despite Semaglutide every op